To advance scientific progress with any cell type, a basic level of knowledge needs to be acquired, including protocols for cell isolation, growth, expansion, differentiation, and more. It requires that characteristics of the cells be observed to determine how they are affected by environmental variation. To date, a significant amount has been learned about mesenchymal stem cells, as 30,697 scientific articles have been published about the cell type.[1] Of those, more than half (17,998) have been published within the last five years.[2] [Read more…]
STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers
Cord Blood Stem Cells, as Compared to Other Stem Cell Alternatives
Since the first stem cell transplant occurred more than 50 years ago (1957), there has been a nearly exponential increase in stem cell transplants, and in late 2012, the millionth stem cell transplant occurred, a landmark event in stem cell medicine. Cord blood stem cells have distinct advantages over other sources, including that they are:
• Younger
• More adaptable
• More pure
These traits result from cord blood stem cells being the earliest (non-controversial) stem cells that can be extracted from a living human, and therefore haven’t been exposed to viruses, chemicals, or pollutants in the environment that can alter cell function.
While bone marrow stem cells are the most commonly recognized type of stem cell used in transplant, cord blood stem cells are increasingly showing advantages over other stem cell sources, including reduced immune reactions (such as GvHD) and a greater flexibility for HLA-mismatched cord blood units to be used in transplant. Although cord blood banks began offering their services in the United States in the mid-1990’s, it is within the past ten-years that the percentage of cord blood transplants has significantly increased.
Today, it is clear that the stem cells contained within cord blood banking have the potential to improve and save lives. Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide. However, many expectant parents still do not fully understand the significance of cord blood storage.
Unfortunately, a study published in the 2006 Journal of Reproductive Medicine showed that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” The study also identified that 84% of prenatal patients expected their obstetricians to be able to provide them with information on the subject of cord blood banking; however, only about 14% were educated about cord blood banking by their nurse or obstetrician.
Subsequently, a 2014 Parent Survey conducted by BioInformant Worldwide, LLC (600+ responses from recent and expectant parents), identified that these percentages have shifted very little since 2006, despite attempts in most countries worldwide to encourage healthcare providers to offer prenatal patients balanced information on public and private cord blood banking options.
To learn more about this market segment, view the and the “Complete 2015-16 U.S. Cord Blood Banking Industry Report.”
Want to be better informed than your competition? Get future stem cell industry updates.
About BioInformant
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Major Announcements in Stem Cell Sector – Cynata, Gamida Cell, Pluristem, Universal Cells, and More
Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think! [Read more…]
Pluristem Fortifies IP Position and Partnering Potential in Japan with Two Key Cell Therapy Patents
In major news released today, Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. Pluristem Therapeutics is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.
Therefore, the patents pertain to the three-dimensional growth of placental and fat cells and the use of placental cells grown with 3D technology:
- Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
- Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”
To learn more about the company, see our recent interview Dr. Racheli Ofir, VP Research & Intellectual Property for Pluristem Therapeutics. Or, read the full press release below, printed with permission from Dr. Ofir. [Read more…]
- « Previous Page
- 1
- …
- 258
- 259
- 260
- 261
- 262
- …
- 309
- Next Page »